PMID- 32815673
OWN - NLM
STAT- MEDLINE
DCOM- 20210624
LR  - 20220531
IS  - 1840-2445 (Electronic)
IS  - 1840-0132 (Linking)
VI  - 18
IP  - 1
DP  - 2021 Feb 1
TI  - Serum total prostate-specific antigen (tPSA): correlation with diagnosis and 
      grading of prostate cancer in core needle biopsy.
PG  - 122-127
LID - 10.17392/1204-21 [doi]
AB  - Aim To investigate the impact of pre-treatment serum total prostate-specific 
      antigen (PSA) level on prevalence of prostate carcinoma detection in prostate 
      core needle biopsy, and its correlation with established prognostic factors. 
      Methods Prostate needle biopsy samples of 115 patients with available 
      pre-treatment serum total PSA (tPSA) level were analysed. For all cases where 
      morphology alone was insufficient, immunohistochemistry was performed using p63, 
      CKHMW and AMACR antibody panel in order to confirm or exclude the existence of 
      prostate carcinoma. Results Statistically significant positive correlation 
      between serum total PSA values and prevalence of finding prostate carcinoma in 
      needle biopsy specimens was found (p=0.011), as well as in the case when the 
      patients were classified into groups according to tPSA levels (p=0.028). Serum 
      total PSA values and levels (level groups) showed significant positive 
      correlation with Gleason score (p=0.029 and p=0.036, respectively) and Grade 
      Group of prostate carcinomas (p=0.044 and p=0.046, respectively). Sensitivity of 
      the screening test by using 4 ng/mL as cut off value for tPSA was 94.12% (CI: 
      80.32-99.28%), specificity 8.64% (CI: 3.55-17.00%), positive predictive value 
      30.19% (CI: 21.65-39.87%) and negative predictive value 77.78% (CI: 
      39.99-97.19%). Conclusion The increase of serum tPSA value increases the 
      likelihood of finding prostate cancer on needle biopsy specimens. Due to such 
      findings and its positive correlation with a grade of prostate cancer, our study 
      indicates that tPSA can still be considered as a useful tool both in detecting 
      and predicting aggressiveness of prostate cancer.
CI  - Copyright(c) by the Medical Assotiation of Zenica-Doboj Canton.
FAU - Camdzic, Nina
AU  - Camdzic N
AD  - Department of Pathology, School of Medicine, University of Sarajevo, Sarajevo, 
      Bosnia and Herzegovina.
FAU - Kuskunovic-Vlahovljak, Suada
AU  - Kuskunovic-Vlahovljak S
AD  - Department of Pathology, School of Medicine, University of Sarajevo, Sarajevo, 
      Bosnia and Herzegovina.
FAU - Doric, Mirsad
AU  - Doric M
AD  - Department of Pathology, School of Medicine, University of Sarajevo, Sarajevo, 
      Bosnia and Herzegovina.
FAU - Radovic, Svjetlana
AU  - Radovic S
AD  - Department of Pathology, School of Medicine, University of Sarajevo, Sarajevo, 
      Bosnia and Herzegovina.
FAU - Lazovic Salcin, Edina
AU  - Lazovic Salcin E
AD  - Department of Pathology, School of Medicine, University of Sarajevo, Sarajevo, 
      Bosnia and Herzegovina.
FAU - Babic, Mirsad
AU  - Babic M
AD  - Department of Pathology, School of Medicine, University of Sarajevo, Sarajevo, 
      Bosnia and Herzegovina.
LA  - eng
PT  - Journal Article
PL  - Bosnia and Herzegovina
TA  - Med Glas (Zenica)
JT  - Medicinski glasnik : official publication of the Medical Association of 
      Zenica-Doboj Canton, Bosnia and Herzegovina
JID - 101250177
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (GPI-Linked Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (PSCA protein, human)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Antigens, Neoplasm
MH  - Biopsy, Large-Core Needle
MH  - GPI-Linked Proteins
MH  - Humans
MH  - Male
MH  - Neoplasm Proteins
MH  - Predictive Value of Tests
MH  - *Prostate-Specific Antigen
MH  - *Prostatic Neoplasms/diagnosis
OTO - NOTNLM
OT  - Gleason score
OT  - grade group
OT  - screening
EDAT- 2020/08/21 06:00
MHDA- 2021/06/25 06:00
CRDT- 2020/08/21 06:00
PHST- 2020/05/14 00:00 [received]
PHST- 2020/06/11 00:00 [revised]
PHST- 2020/07/24 00:00 [accepted]
PHST- 2020/08/21 06:00 [entrez]
PHST- 2020/08/21 06:00 [pubmed]
PHST- 2021/06/25 06:00 [medline]
AID - 10.17392/1204-21 [doi]
PST - ppublish
SO  - Med Glas (Zenica). 2021 Feb 1;18(1):122-127. doi: 10.17392/1204-21.